Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Sarepta Therapeutics's EV/EBITDA was 219.3× on Jul 31, 2026, against 136.8× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 219.3× | +180.8 |
| 2025 | Oct 31, 2025 | 38.5× | −49.3 |
| 2024 | Dec 31, 2024 | 87.8× | – |
See a number that looks wrong?